Technology | Proton Therapy | January 04, 2018

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy

PBS technology paints tumors layer-by-layer for more precise radiation therapy targeting

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy

January 4, 2018 — Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i Proton Therapy System including Hyperscan pencil beam scanning (PBS) technology. Hyperscan PBS introduces novel energy layer switching and automated collimation systems. These advantages enable the S250i system to deliver faster, sharper and more robust PBS proton radiation treatments.

The S250i with Hyperscan PBS has now received FDA and CE mark clearance.

The Mevion S250i system is a compact proton therapy system capable of delivering conformal radiation therapy treatments using Hyperscan pencil beam scanning technology. The design of Hyperscan PBS technology overcomes clinical challenges that were previously faced by first-generation PBS systems.

Pencil beam scanning systems shape the delivered radiation dose by “painting” tumors spot-by-spot and layer-by-layer with sub-atomic particles. Prior to Hyperscan PBS, scanning proton systems struggled with delivery speed, according to Mevion. Long delivery times can undermine the high precision of the treatment due to the target tumor shifting under normal organ motion such as breathing.

Hyperscan PBS uses a compact beam delivery path reducing delivery times to less than 5 seconds for some fields. This “hyper-fast” treatment delivery reduces treatment errors due to the sensitivity to motion that current PBS technologies face when treating tumors affected by organ motion.

In addition, Hyperscan PBS utilizes the Adaptive Aperture proton multi-leaf collimator (pMLC). This technology uses a robotically controlled collimation system, capable of trimming the edges of the beam at every layer of delivery. This capability delivers up to a three times sharper drop off in radiation at the delivery field edge. This improves sparing of healthy tissue and limits unnecessary radiation to sensitive locations.

MedStar Georgetown University Hospital in Washington, D.C. will be the first hospital in the world to offer this latest generation of Hyperscan PBS once final onsite testing is completed in January.

“We are excited to be not only the first and only proton therapy system in the Washington, D.C. area, but also the first in the world to offer these advanced proton therapy treatment capabilities to our patients and community. Currently, patients who seek proton therapy need to leave the metropolitan D.C. area, which can be a significant burden on families,” said Brian T. Collins, M.D., clinical director of MedStar Georgetown Proton Therapy Center. “We will now be delivering advanced proton therapy, fully integrated into our broad set of comprehensive cancer care offerings. This is critical to the patients we serve.”

The Mevion S250i system is based on Mevion’s high-efficiency, low-financial-risk S250 Series platform. The core technology of the S250 Series is what the company calls the world’s only gantry mounted superconducting synchrocyclotron.

For more information: www.mevion.com

Related Content

VIDEO: Clinical Considerations for Proton Therapy

Mevion Achieves CE Mark for S250i Proton Therapy System

Transforming the Outlook on Cancer

Related Content

With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.
News | Proton Therapy | August 30, 2021
August 30, 2021 — IBA (Ion Beam Applications S.A., EURONEX
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality that will one day treat all stages of cancer,announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.

RefleXion Medical announces the sale of its X1 machine to The Center for Cancer and Blood Disorders in Texas. (Photo: Business Wire)

News | Radiation Therapy | August 23, 2021
August 23, 2021 — ...